How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2019 financial year.
ESE is funded through a number of industry and non-industry sources;
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- The list of all industry and non-industry revenue sources in 2019 are listed below:
- Advanced Accelerator Applications
- Aegerion Pharmaceuticals
- AmCad
- Ascendis Pharma
- Avanti Polard Lipids
- Chiasma
- Clinical Endocrinology Trust
- Corcept
- Eli Lilly
- HRA Pharma
- Ipsen
- ITM (Isotopen Technologies Munchen)
- Merck
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Sandoz/Hexal
- Shire/Takeda
- Siemens
- Strongbridge
- Taureon
- The Company of Biologists
- ThermoFisher
- Unipharma
- Wisepress
- Of the revenue into ESE in the 2019 accounts 39.5% was provided by industry
- The highest contribution from a single company represented 17% of the industry revenue and 6% of ESE revenue overall.